Project Grant HT94252410063
Award Date
2/1/24
Completion Date
1/31/26
Dollars Obligated
$310K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
This $309,928 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate ferritin as a biomarker for progression of autosomal polycystic kidney disease. The 2-year project, which began on February 1, 2024, aims to advance scientific knowledge and develop innovative therapies in this area of kidney disease. KUMCRI, a...
The federal Project Grant award, titled "THERAPEUTIC PARAMETERS AND MECHANISM OF ACTION OF ANTI-MIR-17 DRUGS IN ADPKD", is being provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The $1,640,000.00 grant was awarded to The University of Texas Southwestern Medical Center, a leading academic medical research institution, on April 1, 2025. The funding will support advanced biomedical research focused on transforming...
Yale University was awarded an $11,577,868 project grant from the Defense Health Agency to research polycystic kidney disease under the Military Medical Research and Development program (CFDA 12.420). The grant period runs from September 1, 2021 through August 31, 2025. Through this funding, Yale researchers will investigate polycystic kidney disease as a disorder of glomerulotubular synchronization. The Military Medical Research and Development program aims to transform military and public...
This $1,395,000 Project Grant award from the Department of Defense's Defense Health Agency was made to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) on April 1, 2024. The grant is funded under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research related to military medicine, with a focus on areas such as cancer and neurological disorders. The purpose of this 3-year grant is to develop a short peptide-based...
The Department of the Army Medical Command awarded Yale University a $2,639,485 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from December 2021 through November 2025 to investigate inhibition of the IRE1alpha-XBP1 pathway using toyocamycin as a novel approach to inhibit progression of autosomal dominant polycystic kidney and liver disease. The Military Medical Research and Development program supports basic, applied, and...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) supports research into the mechanisms underlying autosomal dominant polycystic kidney disease (ADPKD). The $1,472,604 award to the Children's Hospital Medical Center in Cincinnati, OH aims to elucidate how a second somatic mutation in renal cells affects their behavior and the progression of cystic disease in...
The University of Pittsburgh received a $198,750 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847) to develop a rapid, quantitative platform using yeast to classify how approximately 70 identified mutations in the polycystin-1 (PC1) protein disrupt channel activity with PC2. This research aims to provide new reagents and assays to the scientific and PKD (polycystic kidney disease) community to study the molecular defects of PC1 mutants. The...
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $1,550,000.00 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award, with a performance period from April 1, 2025 to March 31, 2029, will support advanced biomedical research focused on investigating "RBP-J inhibition as a novel latency reversal strategy for HIV-1-related kidney diseases."...
This four-year Project Grant from the Defense Health Agency provides $2,207,793 to investigate ido1 and dysregulated tryptophan metabolism in polycystic kidney disease. The grant supports research from April 1, 2023 through March 31, 2027. The Regents of the University of Colorado, doing business as the University of Colorado Denver, will investigate medical solutions for polycystic kidney disease under the Military Medical Research and Development program. This Defense Health Agency program...
The University of Kansas Medical Center Research Institute, Inc. (KUMCRI) was awarded a $930,000 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on March 1, 2024, supports research to investigate the progression of ductal carcinoma in situ (DCIS) to invasive basal-like breast cancer, with a focus on the role of N-RAS. The research aims to advance scientific knowledge and develop innovative therapies in the...